Search

Your search keyword '"Jean-Pierre Bassand"' showing total 241 results

Search Constraints

Start Over You searched for: Author "Jean-Pierre Bassand" Remove constraint Author: "Jean-Pierre Bassand"
241 results on '"Jean-Pierre Bassand"'

Search Results

1. Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry

2. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

3. Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF

4. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry

5. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

6. Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry

7. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

8. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

9. GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM

10. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

11. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

12. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

13. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

14. Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF

15. Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry

16. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry

17. Comparative effectiveness of oral anticoagulants in everyday practice

18. GARFIELD-AF risk score for mortality, stroke and bleeding within 2 years in patients with atrial fibrillation

19. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

20. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry

21. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

22. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry

23. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

24. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke

25. The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events

26. Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry

27. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants

28. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation

29. GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM

30. Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

31. Invasive cardiovascular needs in South Africa: a view from afar up close

32. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry

33. Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS

34. Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization

35. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents

36. The potential value of intravascular ultrasound imaging in diagnosis of aortic intramural hematoma

38. Beyond Reperfusion Networks in ST-segment Elevation Myocardial Infarction: Assessment of Quality of Care

39. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

40. Propensity Score-Matched Analysis of Effects of Clinical Characteristics and Treatment on Gender Difference in Outcomes After Acute Myocardial Infarction

41. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

42. Barking up the right tree at last: another step closer to a universal definition of bleeding: Figure 1

43. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

44. Right-to-left atrial shunting associated with aortic root aneurysm: A rare cause of platypnea-orthodeoxia syndrome

45. Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction

46. Prognostic value of albuminuria on 1-month mortality in acute myocardial infarction

47. Anemia for Risk Assessment of Patients With Acute Coronary Syndromes

48. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes

49. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk

50. Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes

Catalog

Books, media, physical & digital resources